Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy

BACKGROUND: Extended‐duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net cli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Heart Assoc
Autors principals: Gibson, C. Michael, Korjian, Serge, Chi, Gerald, Daaboul, Yazan, Jain, Purva, Arbetter, Douglas, Goldhaber, Samuel Z., Hull, Russel, Hernandez, Adrian F., Lopes, Renato D., Gold, Alex, Cohen, Alexander T., Harrington, Robert A.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5586307/
https://ncbi.nlm.nih.gov/pubmed/28698258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.006015
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars